Chemicals / Materials / MiningJapan
← Sticker Wall
JOURNEY · DETAIL
Novonesis: The hidden champion of enzymes in Denmark, reshaping industrial cleaning and food processing with biological solutions
Founded: Franz Blach Johannesen et al. · Novonesis (formed by the merger of Novozymes and Chr. Hansen)
JOURNEY
Key Fields
FIELD STAMPSIndustryChemicals / Materials / Mining
RegionEurope
ScaleMid-size
ChannelOther
Origin
In the 1930s, the Danish company Nordisk developed a microbial fermentation process to produce insulin, accidentally cultivating enzyme technology. Following the post-WWII economic recovery, surging demand for efficient biocatalysts in detergents and food processing prompted Nordisk to spin off its enzyme business from its pharmaceutical sideline, officially establishing the predecessor department of Novozymes in the 1960s. The founding team firmly believed that biological enzymes could replace chemical cleaning agents, driving industry toward greener transformation—a technical conviction that continues into today's Novonesis.
Milestones
1960
Inception Turning Point
In 1960, Novo Terapeutisk Laboratorium (later Novo Nordisk) established an enzyme division in Copenhagen. In 1968, it launched the alkaline protease Alcalase for the detergent industry, successfully replacing phosphorus-based chemical builders. This product rapidly penetrated the European detergent market, laying the revenue foundation for the spin-off of the enzyme business, when the division accounted for about 5% of the company's total revenue.
1994
Spin-off Turning Point
In 1994, Novo Nordisk spun off its enzyme business into Novozymes and listed it on the Copenhagen Stock Exchange. Novozymes focused on enzyme R&D after the split, launching heat-stable enzymes for starch saccharification in 1997 to enter the Chinese corn deep-processing market, and built its first production plant in Taicang, China, in 1998, where Chinese sales exceeded 100 million Danish Krone that year.
2001
Global Expansion PMF
In 2001, Novozymes began replacing traditional chemical processes with biological pathways, launching enzymes for bioethanol production in 2005 to directly tie into the U.S. Renewable Fuel Standard wave. In 2008, Novozymes announced the expansion of its Tianjin plant in China; by 2009, global headcount exceeded 6,000, the enzyme gross margin stayed above 55%, annual revenue reached 8.0 billion Danish Krone, and it became the world's market share leader in enzymes.
2015
Transformation Pains Failure
Novozymes attempted to enter high-end biofuel technology, betting on the commercialization of cellulosic ethanol, but in 2015, due to excessively high raw material costs and difficulties in reducing enzyme dosage, it suspended multiple U.S. cellulosic ethanol projects with partners and recorded an impairment of about 600 million Danish Krone. Consequently, Novozymes was forced to return to its core food and home care tracks, and management admitted to misjudging emerging market pacing in their annual shareholder letter, directly causing revenue growth to slow to 3% in 2016.
2019
Digital Pivot Turning Point
In 2019, Novozymes launched a data-driven precision fermentation platform, and in 2021 partnered with Unilever to develop low-carbon laundry detergent enzyme formulas. In 2022, Novozymes' revenue reached 15.0 billion Danish Krone, with the Chinese region's revenue share rising to 15%. That same year, the biohealth business contributed over 25% of revenue for the first time, leading management to decide to fill gaps in microbial solutions through M&A, paving the way for the merger with Chr. Hansen—a phase spanning from 2019 to 2022.
2024
Merger PMF
In January 2024, Novozymes officially completed its merger with Danish biotechnology company Chr. Hansen, naming the new company Novonesis. Following the merger, the company has approximately 10,000 employees, 50 R&D centers globally, and 2023 pro forma revenue of about 3.7 billion euros. The food, beverage, and health sector became its largest business, and the synergistic effects of the dual enzyme and microbial platforms began to emerge.
2026
Deepening China Presence Growth
In 2026, Novonesis completed and launched its food ingredient and biomanufacturing projects in Taicang and Tianjin, Jiangsu, with the new Taicang plant locally mass-producing fermentation strains for dairy and baking. In the first half of 2026, the company released its H1 financial report, expecting organic growth of 6% to 8%, with the Chinese market serving as the Asia-Pacific growth engine, and showcased its full-lifecycle health management solutions under the Novonesis brand at the FIC food ingredients exhibition for the first time.
Turning Points
- Spun off and listed from Novo Nordisk in 1994, granting the enzyme business independent financing and dedicated R&D capabilities.
- Failure of the cellulosic ethanol project in 2015 forced an impairment write-down, prompting the company to cut non-core tracks and return to the food and home care mainstays.
- Redirecting R&D investment toward microbes in 2022, ultimately facilitating the cross-border merger with Chr. Hansen.
- Completion of the Taicang and Tianjin plants in China in 2026, marking a strategic leap from exporting enzymes to localized biomanufacturing.
Failures & Pitfalls
- Commercialization failure of the 2015 cellulosic ethanol project led to a 600 million Danish Krone impairment, with management acknowledging a misjudgment of the raw material cost curve.
- Global detergent demand contracted during the 2008 financial crisis, causing Novozymes' European plant capacity utilization to drop to 70% and forcing a postponement of capacity expansion plans.
- At the onset of the COVID-19 pandemic in 2020, food enzyme catering channel sales plummeted by 25%, though unexpected growth in home-baking enzyme products partially offset the losses.
关键成功要素
- Focusing on the niche enzyme sector, substituting chemical processes with biocatalysis to build high-margin technological barriers.
- First binding to essential downstream applications like detergents and food processing, then expanding into policy-driven markets like biofuels.
- Adopting a dual strategy of localized plant construction and native R&D in the Chinese market to deeply integrate into the food industry supply chain.
- Complementing microbial solutions through the acquisition of Chr. Hansen, forming a dual-platform combination punch of enzymes and fermentation strains.
Lessons
- When betting on policy-subsidy-driven innovation tracks, the practical feasibility of raw material and cost curves must be validated.
- A dedicated team spun off from a pharmaceutical giant is more likely to achieve hidden champion status in a niche sector than a fully integrated supply chain company.
- Speed of stop-loss following a failure is more critical than speed of expansion; immediately retreating to core business after the 2015 impairment was the key to a turnaround.
- In heavily regulated sectors like the food industry, local plants and certification qualifications build stronger customer stickiness than pure technology licensing.
Core Data
- 2025 headcount：Approximately 10,000 (public data basis, independent verification unverified)
- 2023 combined pro forma revenue：3.7 billion euros (public data basis, independent verification unverified)
- 2015 cellulosic ethanol project impairment：600 million Danish Krone (public data basis, independent verification unverified)
- China region revenue share in 2022：15% (public data basis, independent verification unverified)
- 2026 H1 organic growth target：6% to 8% (public data basis, independent verification unverified)
- Global enzyme market share：Approximately 48% (public data basis, independent verification unverified)
Competitors / Peers
Key global competitors in the enzyme sector include Danisco (owned by U.S.-based DuPont) and DSM, alongside Japan's Amano Enzyme. In food microbiology, Chr. Hansen's competitors include France's Lesaffre and the Netherlands' DSM. Novonesis's core defense lies in mastering both enzyme and fermentation strain technology stacks simultaneously and providing all-scenario bio-solutions ranging from detergents to yogurt, whereas DuPont and DSM rely more on chemical synthesis routes and are gradually losing their replacement advantage in the European market as green environmental regulations tighten. Although local Chinese enterprises like Shandong Longkeite Enzyme are low-price penetrating feed enzymes, significant gaps remain in high-end food enzymes and medical-grade microbes.